Lux Capital

Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Atrandi Biosciences is a biotechnology company focusing on next-generation single-cell technology, specifically single-cell eukaryotic DNA sequencing. This innovative approach enables the analysis of genomic alterations and cellular heterogeneity.

Bluenote Health operates as an AI platform for life sciences.

Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.

Nomic is a bioengineering company developing the nELISA platform for measuring proteins at scale and high throughput. They offer protein profiling solutions empowering scientists to decide experiment scope and scale.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Atavistik Bio is a pre-clinical biotechnology company dedicated to discovering and developing novel therapies for metabolic diseases and cancer. The company specializes in identifying metabolite-protein interactions and leveraging nature's allosteric control mechanisms to create innovative drug candidates. By focusing on genetically validated targets, Atavistik Bio aims to pioneer first-in-class treatments that harness these unique biological processes, positioning itself at the forefront of biopharmaceutical advancements.

Cromatic develops a software platform that facilitates outsourced R&D for life sciences companies. It streamlines the process of finding and managing scientific outsourcing partners, allowing clients to focus on core scientific work without needing their own lab infrastructure.

Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.

Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.

Trial Library is an oncology clinical trials company that focuses on improving health equity through its innovative clinical trial technology. The company aims to expand access to cancer precision medicine by creating inclusive research environments that enhance health outcomes. By addressing disparities in the discovery and access to cancer clinical trials, Trial Library seeks to transform the standard of care. Its technology assists in accelerating equitable recruitment for clinical trials, ensuring that a diverse patient population is represented in cancer research.

Anagenex is a biotechnology company developing a novel platform for drug discovery. This platform focuses on challenging targets by combining machine learning with DNA-encoded libraries and proprietary AI models to accelerate small molecule drug discovery.

LatchBio is a biotechnology company founded in 2021 by Alfredo Andere, Kyle Giffin, and Kenny Workman. It focuses on developing a data infrastructure aimed at supporting the open-source biocomputing revolution. The company provides a bioinformatics platform specifically designed for cell and gene therapy startups, offering a modern cloud computing stack that enables biotech labs to manage and execute custom workflows, pipelines, and machine learning models. This platform allows scientists to create bioinformatic queries efficiently, without requiring command-line expertise or the burdens of complex system setups. By streamlining data integration and computational processes, LatchBio helps biotech companies accelerate therapeutic discovery and reduce engineering costs.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Gandeeva Therapeutics is a precision biotechnology company that combines cryogenic electron microscopy (cryo-EM) and machine learning to discover and develop therapeutics by targeting and modulating key protein-protein interactions. Its structure-guided drug discovery platform comprises SPOTLIGHT for target prediction and validation, HYPERFOCUS for hit identification from virtual and fragment libraries, and CRYO-CADD for lead optimization. The company pursues a preclinical oncology program focused on difficult-to-treat cancers with novel protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area of Canada, Gandeeva aims to advance differentiated therapeutics and improve outcomes for patients by leveraging its integrated imaging, modeling, and screening capabilities.

Gameto is a biotechnology company focused on advancing female reproductive health through innovative therapies. Recognizing the significant lack of treatment options in this underserved area, Gameto employs cutting-edge scientific techniques to develop solutions that enhance the quality of life for women. The company utilizes cellular engineering to create a platform that produces engineered ovarian and endometrial cell lines capable of mimicking the functions of natural cells, including hormone production and response. This platform underpins a portfolio of cellular therapeutics aimed at addressing various female reproductive diseases. Gameto's first initiative, Fertilo, targets improvements in in vitro fertilization (IVF) and egg freezing processes, striving to make them shorter, safer, and more effective. Additionally, the company is developing Deovo, an organoid model of the female reproductive system, and Ameno, a cell-based therapy designed to mitigate health issues related to primary ovarian insufficiency and menopause. Through these efforts, Gameto aims to transform the landscape of female reproductive health care.

Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Anagenex is a biotechnology company developing a novel platform for drug discovery. This platform focuses on challenging targets by combining machine learning with DNA-encoded libraries and proprietary AI models to accelerate small molecule drug discovery.

Nomic is a bioengineering company developing the nELISA platform for measuring proteins at scale and high throughput. They offer protein profiling solutions empowering scientists to decide experiment scope and scale.

H1 provides a global healthcare platform that connects life sciences companies, hospitals, academic medical centers, and health systems with providers, enables access to clinical research, helps locate industry experts, and supports benchmarking of organizations. As a trusted source of information on healthcare professionals and institutions, the platform combines real-time data and clinical findings to illuminate the broader healthcare ecosystem. The company, founded in 2017 and based in New York, also offers a healthcare data analytics capability that delivers real-time, end-to-end insights across the data landscape to support therapeutic development—from fundraising and product development to product launch.

Kingdom Supercultures is a Brooklyn-based company established in 2019 that specializes in developing and producing microbial cultures for the food industry. The company focuses on reassembling nature's microbes into innovative combinations, allowing food manufacturers to create new varieties of food with enhanced benefits. Their product line includes Koji, a traditional Japanese ingredient used in miso, sake, and soy sauce, as well as microbial cultures for fermented sodas, beers, and plant-based dairy alternatives. Kingdom Supercultures employs an automated scientific platform that features a comprehensive biobank of Generally Recognized As Safe (GRAS) microbial strains and utilizes advanced algorithms to predict and assemble microbial communities. By providing functional ingredients and biopreservatives, the company aims to support healthy and sustainable food development across various industries, including food, beverage, personal care, and beauty.

LatchBio is a biotechnology company founded in 2021 by Alfredo Andere, Kyle Giffin, and Kenny Workman. It focuses on developing a data infrastructure aimed at supporting the open-source biocomputing revolution. The company provides a bioinformatics platform specifically designed for cell and gene therapy startups, offering a modern cloud computing stack that enables biotech labs to manage and execute custom workflows, pipelines, and machine learning models. This platform allows scientists to create bioinformatic queries efficiently, without requiring command-line expertise or the burdens of complex system setups. By streamlining data integration and computational processes, LatchBio helps biotech companies accelerate therapeutic discovery and reduce engineering costs.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Atavistik Bio is a pre-clinical biotechnology company dedicated to discovering and developing novel therapies for metabolic diseases and cancer. The company specializes in identifying metabolite-protein interactions and leveraging nature's allosteric control mechanisms to create innovative drug candidates. By focusing on genetically validated targets, Atavistik Bio aims to pioneer first-in-class treatments that harness these unique biological processes, positioning itself at the forefront of biopharmaceutical advancements.

Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.

Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Benchling, Inc. delivers a cloud-based informatics platform for life sciences research and development. The platform unifies experiment design, data capture, and collaboration in a single interface, enabling scientists to design, record, and share experiments. It consists of an integrated lab notebook, a biological registration system to track inventory such as plasmids, antibodies, and cell lines, and a molecular biology design and analysis suite that supports end-to-end R&D workflows. Additional modules include Benchling Insights for querying and visualizing structured data and collaboration around it, and Bioregistry for biological entity registration and strain management. Benchling serves researchers in biotechnology and pharmaceutical companies as well as academic and government labs, including research and development managers and principal investigators who need centralized data management and streamlined collaboration. The platform is applied across antibodies, cell therapy, gene therapy, proteins and peptides, vaccines, and industrial biotechnology. Founded in 2012 and based in San Francisco, Benchling enables scientists to design DNA, manage workflows, and accelerate decision-making throughout the R&D lifecycle.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

H1 provides a global healthcare platform that connects life sciences companies, hospitals, academic medical centers, and health systems with providers, enables access to clinical research, helps locate industry experts, and supports benchmarking of organizations. As a trusted source of information on healthcare professionals and institutions, the platform combines real-time data and clinical findings to illuminate the broader healthcare ecosystem. The company, founded in 2017 and based in New York, also offers a healthcare data analytics capability that delivers real-time, end-to-end insights across the data landscape to support therapeutic development—from fundraising and product development to product launch.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Benchling, Inc. delivers a cloud-based informatics platform for life sciences research and development. The platform unifies experiment design, data capture, and collaboration in a single interface, enabling scientists to design, record, and share experiments. It consists of an integrated lab notebook, a biological registration system to track inventory such as plasmids, antibodies, and cell lines, and a molecular biology design and analysis suite that supports end-to-end R&D workflows. Additional modules include Benchling Insights for querying and visualizing structured data and collaboration around it, and Bioregistry for biological entity registration and strain management. Benchling serves researchers in biotechnology and pharmaceutical companies as well as academic and government labs, including research and development managers and principal investigators who need centralized data management and streamlined collaboration. The platform is applied across antibodies, cell therapy, gene therapy, proteins and peptides, vaccines, and industrial biotechnology. Founded in 2012 and based in San Francisco, Benchling enables scientists to design DNA, manage workflows, and accelerate decision-making throughout the R&D lifecycle.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Variant Bio Inc. is a biotechnology company focused on developing therapeutics through the exploration of human genetic diversity. Founded in 2018 and headquartered in Seattle, Washington, the company seeks to identify individuals and populations exhibiting extreme outlier traits relevant to various medical conditions. By employing advanced sequencing technologies, statistical genetics, and machine learning, Variant Bio analyzes the genetic underpinnings of these traits to uncover new therapeutic targets. The company's mission is to enhance global health by addressing unmet medical needs, particularly in areas such as neurodegenerative, autoimmune, and cardiometabolic diseases.

Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.

3Scan develops robotic microscopy tools and software for large-scale tissue analysis and three-dimensional visualization. It builds devices that automate tissue sectioning and integrates automation with machine learning and computer vision to extract spatial data from tissue and generate detailed three-dimensional representations and quantitative analyses of complex anatomical structures. These capabilities enable higher-throughput histology and broader image analysis for researchers and clinicians, supporting advances in diagnostics and therapeutics for diseases such as cancer, neurodegenerative conditions, and cardiovascular disease.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

3Scan develops robotic microscopy tools and software for large-scale tissue analysis and three-dimensional visualization. It builds devices that automate tissue sectioning and integrates automation with machine learning and computer vision to extract spatial data from tissue and generate detailed three-dimensional representations and quantitative analyses of complex anatomical structures. These capabilities enable higher-throughput histology and broader image analysis for researchers and clinicians, supporting advances in diagnostics and therapeutics for diseases such as cancer, neurodegenerative conditions, and cardiovascular disease.

Capella BioScience is engaged in the discovery and development of monoclonal antibodies (mAbs) for therapeutic applications. The company utilizes proprietary technologies to create and commercialize mAbs targeting oncology, autoimmune diseases, and other medical conditions. Capella BioScience collaborates with biotechnology firms and academic institutions to enhance its research and development efforts, aiming to advance innovative therapeutic solutions in the medical field.

Experiment Inc. is an online crowdfunding platform dedicated to advancing scientific research across a broad range of disciplines, including biology, chemistry, computer science, medicine, and anthropology. Founded in 2010 and based in San Francisco, California, the company allows users to discover and support innovative scientific projects. Researchers from over 150 institutions and universities globally utilize the platform to secure funding for their work, fostering a collaborative environment for scientific exploration and discovery. Originally known as Microryza Inc., the company rebranded to Experiment Inc. in February 2014 to better reflect its mission and focus on science.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.